规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | CD73-IN-3, derived from example 2 of patent WO2019168744 A1, is a potent inhibitor of CD73 (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3 shows promise for cancer research [1]. |
体外研究 | CD73-IN-3 suppresses CD73 activity in human serum with an EC50 of 0.213 μM. At concentrations of 0.52 μM, 1.56 μM, and 4.68 μM, CD73-IN-3 reduces CD73 activity in human serum by 56.8%, 71.7%, and 76.9%, respectively [1]. In the N Calu6 human cell assay targeting CD73, the IC50 of CD73-IN-3 against CD73 is 0.0073 uM [1]. |
Concentration | Treated Time | Description | References | |
Bone marrow-derived macrophages (BMDMs) | 1 μM | 24 h | To investigate the inhibitory effect of LY3475070 on CD73 expression in BMDMs and its impact on T cell function. Results showed that LY3475070 reversed the senescence-induced upregulation of CD73 in BMDMs and restored T cell proliferation and activity. | Theranostics. 2024 Jan 20;14(3):1224-1240. |
Administration | Dosage | Frequency | Description | References | ||
C57BL/6 mice | LLC subcutaneous tumor model | Oral gavage | 50 mg/kg | Once daily for five days | To evaluate the effect of LY3475070 on tumor growth and antitumor immunity in the senescent microenvironment. Results showed that LY3475070 significantly suppressed tumor growth and activated CD8+ T cell-mediated antitumor immunity. | Theranostics. 2024 Jan 20;14(3):1224-1240. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.49mL 0.70mL 0.35mL |
17.46mL 3.49mL 1.75mL |
34.92mL 6.98mL 3.49mL |
CAS号 | 2375815-63-5 |
分子式 | C15H18N4O2 |
分子量 | 286.33 |
SMILES Code | C(C)(C)[C@@H]1[C@](C1)(C=2C=C(N=NC2C)C=3C(=O)NC(=O)NC3)[H] |
MDL No. | MFCD01123336 |
别名 | LY-3475070 |
运输 | 蓝冰 |
InChI Key | WHRUIISQCORGKK-KOLCDFICSA-N |
Pubchem ID | 152262911 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
溶解方案 |
DMSO: 105 mg/mL(366.71 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|